4-({[2-fluoro-3-(2-hydroxyethoxy)-5-methoxyphenyl]-(5-oxo-1-pyrimidin-2-yl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)methyl}amino)benzamidine acetate | 951803-95-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-({[2-fluoro-3-(2-hydroxyethoxy)-5-methoxyphenyl]-(5-oxo-1-pyrimidin-2-yl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)methyl}amino)benzamidine acetate
• 英文别名: 4-({[2-fluoro-3-(2-hydroxyethoxy)-5-methoxyphenyl]-(5-oxo-1-pyrimidin-2-yl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)methyl}amino)benzamidine acetic acid salt；acetic acid;4-[[[2-fluoro-3-(2-hydroxyethoxy)-5-methoxyphenyl]-(5-oxo-1-pyrimidin-2-yl-4H-1,2,4-triazol-3-yl)methyl]amino]benzenecarboximidamide
• CAS: 951803-95-5
• 化学式: C₂H₄O₂*C₂₃H₂₃FN₈O₄
• 分子量: 554.538
• InChiKey: GJLZFYFVDPMICW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.45
• 重原子数：
  40
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  208
• 氢给体数：
  6
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  4-({[2-fluoro-3-(2-hydroxyethoxy)-5-methoxyphenyl]-(5-oxo-1-pyrimidin-2-yl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)methyl}amino)benzamidine acetate 在 三乙胺 、 fluoro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 N-[1-amino-1-(4-{[[2-fluoro-3-(2-hydroxyethoxy)-5-methoxyphenyl]-(5-oxo-1-pyrimidin-2-yl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)methyl]amino}phenyl)methylidene]benzamide
  参考文献：
  名称：

  [EN] PRODRUG OF TRIAZOLONE COMPOUND
  [FR] PROMÉDICAMENT DE COMPOSÉ DE TRIAZOLONE

  摘要：

  通过口服以下式（I）所代表的化合物：具有对血液凝固因子VIIa具有优异的抑制作用和抗凝作用的化合物（IV）的血液水平达到足以表达其药理作用的水平。因此，本发明的化合物可用作治疗和/或预防由血栓形成引起的疾病的药物。

  公开号：

  WO2011145747A1

文献信息

• Triazolone derivatives
  申请人：Clark Richard

  公开号：US20080015199A1

  公开（公告）日：2008-01-17

  A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R 1a , R 1b , R 1c and R 1d each independently represent hydrogen, etc.; R 2 represents optionally substituted phenyl, etc.; R 3 represents optionally substituted C6-10 aryl, etc.; and Z 1 and Z 2 each independently represent hydrogen]

  以下一般式（1）表示的化合物，其盐或上述化合物的水合物是一种新型化合物，可用于治疗和/或预防与血栓形成相关的疾病，并且具有适当的物理化学稳定性，更安全。 [其中R1a，R1b，R1c和R1d分别独立表示氢等；R2表示可选择取代的苯基等；R3表示可选择取代的C6-10芳基等；Z1和Z2分别独立表示氢]
• TRIAZOLONE DERIVATIVES
  申请人：CLARK Richard

  公开号：US20100190783A1

  公开（公告）日：2010-07-29

  A Compound represented by the following general formula (1): wherein R 1a , R 1b , R 1c and R 1d each independently represent hydrogen, etc.; R 2 represents optionally substituted phenyl, etc.; R 3 represents optionally substituted C6-10 aryl, etc.; and Z 1 and Z 2 each independently represent hydrogen or salts thereof or hydrates of the foregoing.

  以下是通式（1）表示的化合物：其中R1a，R1b，R1c和R1d各自独立地表示氢等；R2表示可选取代的苯基等；R3表示可选取代的C6-10芳基等；Z1和Z2各自独立地表示氢或其盐或其水合物。
• PRODRUG OF TRIAZOLONE COMPOUND
  申请人：Clark Richard

  公开号：US20130053563A1

  公开（公告）日：2013-02-28

  By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.

  通过口服下述式（I）所表示的化合物：血液中的化合物（IV）：具有对血凝因子VIIa的优异抑制作用和抗凝作用，达到足以表现其药理作用的水平。因此，本发明的化合物可用作治疗和/或预防由血栓形成引起的疾病的药物。
• Prodrug of triazolone compound
  申请人：Clark Richard

  公开号：US08436009B2

  公开（公告）日：2013-05-07

  By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.

  通过口服给予以下化学式（I）所代表的化合物，可以使具有出色抑制血液凝固因子VIIa和抗凝作用的化合物（IV）的血液水平达到足以表现其药理作用的水平。因此，本发明的化合物可用作治疗和/或预防由血栓形成引起的疾病的药物。
• TRIAZOLONE DERIVATIVE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2000465A1

  公开（公告）日：2008-12-10

  A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen]

  由以下通式（1）代表的化合物、其盐类或前述化合物的水合物是一种新型化合物，可用于治疗和/或预防与血栓形成有关的疾病，且具有较高的安全性和适当的理化稳定性。 [其中 R1a、R1b、R1c 和 R1d 各自独立地代表氢等；R2 代表任选取代的苯基等；R3 代表任选取代的 C6-10 芳基等；Z1 和 Z2 各自独立地代表氢］